

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
23 March 2006 (23.03.2006)

PCT

(10) International Publication Number
WO 2006/030032 A1

(51) International Patent Classification:

C07D 213/64 (2006.01) **C07D 409/10** (2006.01)
C07D 401/10 (2006.01) **A61K 31/4412** (2006.01)
C07D 407/10 (2006.01) **A61P 25/00** (2006.01)
C07D 413/10 (2006.01)

(21) International Application Number:

PCT/EP2005/054636

(22) International Filing Date:

16 September 2005 (16.09.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0420722.1 17 September 2004 (17.09.2004) GB

(71) Applicants (for all designated States except US):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). **ADDEX PHARMACEUTICALS S.A.** [CH/CH]; 12, Chemin des Aulx, CH-1228 Plan-lès-Ouates (Geneva) (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **IMOGAI, Hassan, Julien** [FR/FR]; c/o ADDEX Pharmaceuticals S.A., 12, Chemin des Aulx, CH-1228 Plan-lès-Ouates (Geneva) (CH). **CID-NÚÑEZ, José, Maria** [ES/ES]; Johnson & Johnson Pharmaceutical Research and Development, Division of Janssen-Cilag, S.A. Calle, Jarama, 75 Poligono Industrial, E-45007 Toledo (ES). **DUVEY, Guillaume, Albert, Jacques** [FR/FR]; ADDEX Pharmaceuticals S.A., 12, Chemin des Aulx, CH-1228 Plan-lès-Ouates (Geneva) (CH). **BOLEA, Christelle, Martine** [FR/CH]; ADDEX Pharmaceuticals S.A., 12, Chemin des Aulx, CH-1228 Plan-lès-Ouates (Geneva) (CH). **NHEM, Vanthéa** [FR/FR]; ADDEX Pharmaceuticals S.A., 12, Chemin des Aulx, CH-1228 Plan-lès-Ouates (Geneva) (CH). **FINN, Terry, Patrick** [GB/CH]; ADDEX Pharmaceuticals S.A., 12, Chemin des Aulx, CH-1228 Plan-lès-Ouates (Geneva) (CH). **LE POUL, Emmanuel, Christian** [FR/FR]; ADDEX Pharmaceuticals S.A., 12, Chemin des Aulx, CH-1228 Plan-lès-Ouates (Geneva) (CH).

ROCHER, Jean-Philippe, François, Christian [FR/FR]; ADDEX Pharmaceuticals S.A., 12, Chemin des Aulx, CH-1228 Plan-lès-Ouates (Geneva) (CH). **LÜTJENS, Robert, Johannes** [DE/CH]; ADDEX Pharmaceuticals S.A., 12, Chemin des Aulx, CH-1228 Plan-lès-Ouates (Geneva) (CH).

(74) Agent: **CAMPBELL, Neil**; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO,

[Continued on next page]

(54) Title: NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS



(57) Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) X R¹ N Y (I) R² R³ wherein all radicals are defined in the application. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

WO 2006/030032 A1



SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,*

GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- *of inventorship (Rule 4.17(iv)) for US only*

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.